17 янв. 2024 г. · Casgevy was approved for use in the treatment of sickle cell disease on December 8, 2023 and became the first medicine available in the United ...

21 февр. 2024 г. · December 8, 2023 Summary Basis for Regulatory Action - CASGEVY · Approval History, Letters, Reviews, and Related Documents - CASGEVY · Approval ...

8 дек. 2023 г. · Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9, a type of genome editing technology.

16 янв. 2024 г. · The FDA decision came 2 weeks after the United Kingdom became the first country to approve CASGEVY, with Bahrain following suit a week later.

CASGEVY Makes History as FDA Approves First CRISPR/Cas9 Genome Edited Therapy. Hum Gene Ther. 2024 Jan;35(1-2):1-4. doi: 10.1089/hum.2023.29263.bfs.

16 янв. 2024 г. · Aside from FDA approval, CASGEVY™ has gained approval for transfusion-dependent thalassaemia by the UK's Medicines & Healthcare products ...

8 дек. 2023 г. · “CASGEVY's approval by the FDA is momentous: it is the first CRISPR-based gene-editing therapy to be approved in the U.S. As importantly, ...

16 янв. 2024 г. · Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia · Low levels ...

16 янв. 2024 г. · CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval ... CASGEVY is approved for certain indications in multiple ...

It was approved in the United States for the treatment of sickle cell disease in December 2023 and for the treatment of transfusion-dependent beta thalassemia ... Medical uses · History · Society and culture